Glaukos Co. (NYSE:GKOS) Shares Bought by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund increased its position in Glaukos Co. (NYSE:GKOSGet Rating) by 3.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,820 shares of the medical instruments supplier’s stock after buying an additional 558 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Glaukos were worth $842,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of GKOS. Bank of New York Mellon Corp raised its position in shares of Glaukos by 0.6% in the first quarter. Bank of New York Mellon Corp now owns 481,228 shares of the medical instruments supplier’s stock valued at $27,825,000 after buying an additional 2,843 shares during the last quarter. HighTower Advisors LLC acquired a new position in shares of Glaukos in the first quarter valued at approximately $208,000. Natixis Advisors L.P. acquired a new position in shares of Glaukos in the first quarter valued at approximately $674,000. Bank of Montreal Can increased its position in Glaukos by 14.2% during the first quarter. Bank of Montreal Can now owns 20,031 shares of the medical instruments supplier’s stock worth $1,164,000 after purchasing an additional 2,485 shares during the last quarter. Finally, MetLife Investment Management LLC increased its position in Glaukos by 54.8% during the first quarter. MetLife Investment Management LLC now owns 25,057 shares of the medical instruments supplier’s stock worth $1,449,000 after purchasing an additional 8,866 shares during the last quarter. Institutional investors and hedge funds own 92.17% of the company’s stock.

Glaukos Trading Down 2.0 %

GKOS opened at $48.17 on Wednesday. The stock has a market capitalization of $2.30 billion, a PE ratio of -25.35 and a beta of 1.23. The firm’s fifty day moving average price is $45.75 and its 200 day moving average price is $50.05. The company has a debt-to-equity ratio of 0.64, a current ratio of 7.40 and a quick ratio of 6.84. Glaukos Co. has a 12-month low of $33.33 and a 12-month high of $64.49.

Glaukos (NYSE:GKOSGet Rating) last issued its earnings results on Wednesday, November 2nd. The medical instruments supplier reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.08. The company had revenue of $71.27 million for the quarter, compared to analysts’ expectations of $67.88 million. Glaukos had a negative net margin of 31.45% and a negative return on equity of 16.16%. As a group, research analysts expect that Glaukos Co. will post -2.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and set a $57.00 price target for the company in a research report on Monday, December 12th. JPMorgan Chase & Co. upgraded shares of Glaukos from an “underweight” rating to a “neutral” rating and decreased their price objective for the stock from $48.00 to $42.00 in a research note on Monday, December 19th. StockNews.com downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday. Stephens decreased their price objective on shares of Glaukos from $69.00 to $68.00 and set an “overweight” rating for the company in a research note on Wednesday, December 28th. Finally, Piper Sandler boosted their price objective on shares of Glaukos from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Thursday, November 3rd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $56.67.

Glaukos Profile

(Get Rating)

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.

See Also

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Co. (NYSE:GKOSGet Rating).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.